Ca2+ influx through L-type Ca2+ channels and transient receptor potential channels activates pathological hypertrophy signaling

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 5, 2012, Pages 657-667

  Gao, Hui ^a   Wang, Fang ^a   Wang, Wei ^a   Makarewich, Catherine A ^a   Zhang, Hongyu ^a   Kubo, Hajime ^a   Berretta, Remus M ^a   Barr, Larry A ^a   Molkentin, Jeffery D ^b   Houser, Steven R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Hypertrophy; L type calcium channel; Nuclear factor of activated T cells; Transient receptor potential channel; Ventricular myocyte

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; ADENOVIRUS VECTOR; CALCINEURIN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; GREEN FLUORESCENT PROTEIN; NICKEL; NIFEDIPINE; TRANSCRIPTION FACTOR NFAT; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CAT; CELL NUCLEUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENCY; HEART VENTRICLE HYPERTROPHY; MUSCLE CELL; NEWBORN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CALCINEURIN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CALCIUM SIGNALING; CARDIOMEGALY; CELL NUCLEUS; CELLS, CULTURED; HEART VENTRICLES; IMIDAZOLES; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; NICKEL; NIFEDIPINE; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TRPC CATION CHANNELS; VENTRICULAR REMODELING;

ADENOVIRIDAE; FELIDAE; RATTUS;

EID: 84867401284     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.08.005     Document Type: Article

References (64)

1. 2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes?. Sci Signal 2008, 1. [pe31].
2. Bers D.M., Guo T. Calcium signaling in cardiac ventricular myocytes. Ann N Y Acad Sci 2005, 1047:86-98.
3. Chen X., Nakayama H., Zhang X., Ai X., Harris D.M., Tang M., et al. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. J Mol Cell Cardiol 2011, 50:460-470.
4. Semsarian C., Ahmad I., Giewat M., Georgakopoulos D., Schmitt J.P., McConnell B.K., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002, 109:1013-1020.
5. Ago T., Yang Y., Zhai P., Sadoshima J. Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload. J Cardiovasc Transl Res 2010, 3:304-313.
6. 2+ channel is required for pressure overload-induced cardiac hypertrophy in mice. Circ Res 2009, 104:522-530.
7. 2+ channel blockers. Life Sci 2008, 82:554-560.
8. Wu X., Eder P., Chang B., Molkentin J.D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc Natl Acad Sci 2010, 107:7000-7005.
9. Nakayama H., Wilkin B.J., Bodi I., Molkentin J.D. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J 2006, 20:1660-1670.
10. Onohara N., Nishida M., Inoue R., Kobayashi H., Sumimoto H., Sato Y., et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 2006, 25:5305-5316.
11. Kuwahara K., Wang Y., McAnally J., Richardson J.A., Bassel-Duby R., Hill J.A., et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 2006, 116:3114-3126.
12. 2+ signalling and gene expression. J Physiol 2004, 554:309-320.
13. Xia Y., McMillin J.B., Lewis A., Moore M., Zhu W.G., Williams R.S., et al. Electrical stimulation of neonatal cardiac myocytes activates the NFAT3 and GATA4 pathways and up-regulates the adenylosuccinate synthetase 1 gene. J Biol Chem 2000, 275:1855-1863.
14. 2+ channel antagonist inhibits hypertrophic signaling without reducing cardiac contractility/novelty and significance. Circ Res 2012, 110:669-674.
15. Molkentin J.D., Lu J.-R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
16. Wilkins B.J., Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004, 322:1178-1191.
17. Bodi I., Mikala G., Koch S.E., Akhter S.A., Schwartz A. The L-type calcium channel in the heart: the beat goes on. J Clin Invest 2005, 115:3306-3317.
18. Viola H.M., Macdonald W.A., Tang H., Hool L.C. The L-type Ca(2+) channel as a therapeutic target in heart disease. Curr Med Chem 2009, 16:3341-3358.
19. Richard S., Perrier E., Fauconnier J., Perrier R., Pereira L., Gomez A.M., et al. 'Ca(2+)-induced Ca(2+) entry' or how the L-type Ca(2+) channel remodels its own signalling pathway in cardiac cells. Prog Biophys Mol Biol 2006, 90:118-135.
20. Kleiman R.B., Houser S.R. Calcium currents in normal and hypertrophied isolated feline ventricular myocytes. Am J Physiol 1988, 255:H1434-H1442.
21. Rannou F., Sainte-Beuve C., Oliviero P., Do E., Trouvé P., Charlemagne D. The effects of compensated cardiac hypertrophy on dihydropyridine and ryanodine receptors in rat, ferret and guinea-pig hearts. J Mol Cell Cardiol 1995, 27:1225-1234.
22. Meszaros J., Coutinho J., Bryant S., Ryder K., Hart G. L-type calcium current in catecholamine-induced cardiac hypertrophy in the rat. Exp Physiol 1997, 82:71-83.
23. Momtaz A., Coulombe A., Richer P., Mercadier J.-J., Coraboeuf E. Action potential and plateau ionic currents in moderately and severely DOCA-salt hypertrophied rat hearts. J Mol Cell Cardiol 1996, 28:2511-2522.
24. Gómez A.M., Valdivia H.H., Cheng H., Lederer M.R., Santana L.F., Cannell M.B., et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997, 276:800-806.
25. 2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 2002, 91:517-524.
26. Mukherjee R., Spinale F.G. L-type calcium channel abundance and function with cardiac hypertrophy and failure: a review. J Mol Cell Cardiol 1998, 30:1899-1916.
27. Strand A.H., Gudmundsdottir H., Os I., Smith G., Westheim A.S., Bjørnerheim R., et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20years. J Hypertens 2006, 24:905-913.
28. Schlaich M.P., Kaye D.M., Lambert E., Hastings J., Campbell D.J., Lambert G., et al. Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens 2005, 23:1077-1082.
29. Kelm M., Schäfer S., Mingers S., Heydthausen M., Vogt M., Motz W., et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996, 14:1357-1364.
30. Shimada T., Yoshiyama M., Takeuchi K., Omura T., Takemoto Y., Kim S., et al. Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. Cardiovasc Res 1998, 37:618-626.
31. Massart P.-E., Donckier J., Kyselovic J., Godfraind T., Heyndrickx G.R., Wibo M. Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. Hypertension 1999, 34:1197-1201.
32. Schwitter J., DeMarco T., Globits S., Sakuma H., Klinski C., Chatterjee K., et al. Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication. J Heart Lung Transplant 1999, 18:1003-1013.
33. 2+ response in mutant sarcomere proteinmediated familial hypertrophic cardiomyopathy. J Clin Invest 2000, 106:1351-1359.
34. Gao F., Gong B., Christopher T.A., Lopez B.L., Karasawa A., Ma X.L. Anti-apoptotic effect of benidipine, a long-lasting vasodilating calcium antagonist, in ischaemic/reperfused myocardial cells. Br J Pharmacol 2001, 132:869-878.
35. Nuss H.B., Houser S.R. Effect of duration of depolarisation on contraction of normal and hypertrophied feline ventricular myocytes. Cardiovasc Res 1994, 28:1482-1489.
36. Cribbs L.L., Martin B.L., Schroder E.A., Keller B.B., Delisle B.P., Satin J. Identification of the t-type calcium channel (Ca(v)3.1d) in developing mouse heart. Circ Res 2001, 88:403-407.
37. Qu Y., Boutjdir M. Gene expression of SERCA2a and L- and T-type Ca channels during human heart development. Pediatr Res 2001, 50:569-574. [November].
38. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993, 73:777-782.
39. 2+ channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol 1999, 31:1617-1625.
40. 2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res 2000, 46:442-449.
41. Ferron L., Capuano V., Ruchon Y., Deroubaix E., Coulombe A., Renaud J.-F. Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels. Circ Res 2003, 93:1241-1248.
42. Izumi T., Kihara Y., Sarai N., Yoneda T., Iwanaga Y., Inagaki K., et al. Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro. Circulation 2003, 108:2530-2535.
43. 2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes. Circ Res 2008, 103:1109-1119.
44. 2+ channels in the heart. Cell Calcium 2006, 40:205-220.
45. 2+ channel blockade prevents sudden death in mice with heart failure. Circulation 2009, 120:743-752.
46. 2+ current antagonizes cardiac hypertrophy through a NOS3-dependent mechanism in mice. J Clin Invest 2009, 119:3787-3796.
47. Hofmann T., Schaefer M., Schultz G., Gudermann T. Transient receptor potential channels as molecular substrates of receptor-mediated cation entry. J Mol Med 2000, 78:14-25.
48. Nelson P.L., Beck A., Cheng H. Transient receptor proteins illuminated: current views on TRPs and disease. Vet J 2011, 187:153-164.
49. Eder P., Molkentin J.D. TRPC channels as effectors of cardiac hypertrophy. Circ Res 2011, 108:265-272.
50. Inoue R., Jensen L.J., Shi J., Morita H., Nishida M., Honda A., et al. Transient receptor potential channels in cardiovascular function and disease. Circ Res 2006, 99:119-131.
51. Guinamard R., Bois P. Involvement of transient receptor potential proteins in cardiac hypertrophy. Biochim Biophys Acta (BBA) - Mol Basis Dis 2007, 1772:885-894.
52. Bush E.W., Hood D.B., Papst P.J., Chapo J.A., Minobe W., Bristow M.R., et al. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem 2006, 281:33487-33496.
53. Simpson P., Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res 1982, 50:101-116.
54. Gaughan J.P., Hefner C.A., Houser S.R. Electrophysiological properties of neonatal rat ventricular myocytes with alpha 1-adrenergic-induced hypertrophy. Am J Physiol Heart Circ Physiol 1998, 275:H577-H590.
55. Silver L.H., Hemwall E.L., Marino T.A., Houser S.R. Isolation and morphology of calcium-tolerant feline ventricular myocytes. Am J Physiol 1983, 245:H891-H896.
56. Alibin C.P., Kopilas M.A., Anderson H.D.I. Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid. J Biol Chem 2008, 283:10707-10715.
57. Anderson H.D.I., Wang F., Gardner D.G. Role of the epidermal growth factor receptor in signaling strain-dependent activation of the brain natriuretic peptide gene. J Biol Chem 2004, 279:9287-9297.
58. Wang W., Zhang H., Gao H., Kubo H., Berretta R.M., Chen X., et al β1-Adrenergic receptor activation induces mouse cardiac myocyte death through both L-type calcium channel-dependent and -independent pathways. Am J Physiol Heart Circ Physiol 2010, 299:H322-H331.
59. MacDonnell S.M., Weisser-Thomas J., Kubo H., Hanscome M., Liu Q., Jaleel N., et al. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes. Circ Res 2009, 105:316-325.
60. Wilkins B.J., Dai Y.S., Bueno O.F., Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004, 94:110-118.
61. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999, 100:999-1008.
62. Song Q., Schmidt A.G., Hahn H.S., Carr A.N., Frank B., Pater L., et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 2003, 111:859-867.
63. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
64. Seth M., Zhang Z.-S., Mao L., Graham V., Burch J., Stiber J., et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ Res 2009, 105:1023-1030.